SCHEDULE: Armistice Capital Reports 3.76% Stake in AngioDynamics

Armistice Capital, LLC and Steven Boyd have reported a 3.76% beneficial ownership stake in AngioDynamics Inc., totaling 1,527,815 shares.

Summary

• Armistice Capital, LLC and Steven Boyd are the reporting persons for this beneficial ownership statement.
• They collectively beneficially own 1,527,815 shares of AngioDynamics Inc. Common Stock.
• This ownership represents 3.76% of the total outstanding shares of the class.
• The percentage is calculated based on 40,633,885 shares outstanding as of May 31, 2025, as reported in AngioDynamics Inc.'s 10-K filed on July 18, 2025.
• Armistice Capital, LLC, acting as the investment manager for Armistice Capital Master Fund Ltd., exercises both voting and investment power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of AngioDynamics Inc.

Sentiment

Score: 5

Explanation: This is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 1) indicating a passive investment stake, which typically carries a neutral sentiment as it does not convey positive or negative operational or financial news about the issuer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Indicates a significant institutional investor, Armistice Capital, holds a notable stake, which could be viewed positively by other investors as a vote of confidence, though the filing states the shares are held in the ordinary course of business and not for control purposes.

Key Dates

Keywords

AngioDynamics, ANGI, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Investment Management, Common Stock